Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA-ESMO Workshop on Single-Arm Trials in Oncology

EMA ESMO Single ArmTrials in Oncology Workshop
Start date
30 Jun 2016
End date
30 Jun 2016
London, United Kingdom

Single-arm trials (SATs) have led to regulatory approval of oncology products in case of dramatic activity in well-defined populations with high unmet medical need. Further, when randomised-controlled trials are not possible, SATs augmented with statistical approaches may become the standard basis of evidence of efficacy for new applications.

However, what constitutes dramatic activity and high unmet medical need is often debated and there is no regulatory guidance on cancer drug development in these situations and how to manage the remaining uncertainties optimally.

This workshop, organised by the European Medicines Agency (EMA) in partnership with ESMO, debated the experience gained with these types of approvals, the strengths and weaknesses of different approaches, explored the views of different stakeholders and underlying principles, and discussed the need and appropriateness for further regulatory guidance.

View the slide presentations from the workshop


F. Pignatti (EMA) and P. Casali (ESMO)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.